Apyx (APYX) Upgraded to Buy: Here's What You Should Know

Core Viewpoint - Apyx Medical (APYX) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [3]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3]. Earnings Estimate Revisions - Apyx is projected to earn -$0.70 per share for the fiscal year ending December 2024, reflecting a year-over-year decline of 55.6% [5]. - Over the past three months, the Zacks Consensus Estimate for Apyx has increased by 6.7%, indicating a positive trend in earnings estimates [5]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [4]. - Apyx's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [7].